



## Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2013

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (May 3, 2013 - 6:00 p.m.) – As of April 30, 2013, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

**April 30, 2013**

Shares outstanding	215,324,761
Exercisable voting rights	226,601,592
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*	231,315,616

(\*) Shares held by the Company, either in treasury or under the liquidity contract.

### **About Essilor**

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog™ and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of nearly €5 billion in 2012 and employs around 50,700 people in some 100 countries. It operates 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit [www.essilor.com](http://www.essilor.com).

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.